Amphastar Pharmaceuticals, Inc.
Cash Flow Statement
| Line Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Operating Activities | ||||||||
| Net Income | $98.1M | $159.5M | $137.5M | $91.4M | $62.1M | $1.4M | $48.9M | $-5.7M |
| Depreciation & Amortization | — | — | $25.7M | $12.6M | $10.2M | $9.0M | $7.1M | $6.1M |
| Depreciation | $31.6M | $28.2M | $25.2M | $23.8M | $22.2M | $20.5M | $17.1M | $14.5M |
| Amortization | $25.0M | $24.7M | $12.8M | $954.0K | $1.1M | $1.0M | $1.0M | $2.0M |
| Stock-Based Compensation | $27.3M | $24.4M | $20.2M | $17.9M | $18.7M | $20.5M | $17.3M | $16.7M |
| Net Cash from Operating Activities | $156.1M | $213.4M | $183.5M | $89.2M | $98.0M | $57.3M | $41.8M | $38.2M |
| Investing Activities | ||||||||
| Capital Expenditures | $34.9M | $41.0M | $38.2M | $24.0M | $27.5M | $33.9M | $41.6M | $46.8M |
| Business Acquisitions | — | — | — | — | — | — | — | — |
| Net Cash from Investing Activities | $-70.3M | $-124.9M | $-649.1M | $-32.8M | $-28.7M | $-36.4M | $-50.5M | $-42.2M |
| Financing Activities | ||||||||
| Dividends Paid | — | — | — | — | — | — | — | — |
| Stock Repurchases | $75.6M | $85.5M | $58.1M | $39.9M | $28.9M | $24.4M | $22.3M | $25.0M |
| Net Cash from Financing Activities | $-67.4M | $-81.0M | $454.1M | $-26.4M | $-37.0M | $-2.2M | $-3.8M | $25.0M |
| Net Change in Cash | $18.6M | $7.3M | $-11.8M | $29.7M | $32.1M | $19.0M | $-12.7M | $20.7M |
| Free Cash Flow | $121.2M | $172.3M | $145.3M | $65.1M | $70.5M | $23.4M | $207.0K | $-8.6M |